Management of diabetic dyslipidemia

Endocrinology and Metabolism Clinics of North America

Volumn 34, Issue 1, 2005, Pages 1-25

  Solano, Maria Del Pilar ^a   Goldberg, Ronald B ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; CERIVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; NICOTINIC ACID; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; FOLLOW UP; HEALTH EDUCATION; HEALTH PROGRAM; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; LIFESTYLE; LIVER TOXICITY; LONG TERM CARE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; SKIN TINGLING; SMOKING CESSATION; STROKE; SURVIVAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 14744287771     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2005.01.001     Document Type: Review

References (106)

1. M.I. Harris, and P.S. Entmacher Mortality from diabetes M.I. Harris R.F. Hamman Diabetes in America 1985 US Government Printing Office Washington, DC 1 48 Publication #NIH85-1468
2. J. Stamler, O. Vaccaro, and J.D. Neaton Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
3. W.B. Kannel, and D.L. McGee Diabetes and cardiovascular risk factors: the Framingham study Circulation 59 1979 8 13
4. P. Savage Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention Ann Intern Med 1241 1996 123 126
5. K. Pyorala, M. Laakso, and M. Uusitupa Diabetes and atherosclerosis: an epidemiologic view Diabetes Metab Rev 3 1987 463 524
6. S.M. Haffner, S. Lehto, and T. Ronnemaa Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
7. F.B. Hu, M.J. Stampfer, and C. Solomon Diabetes mellitus and mortality from all causes and coronary heart disease in women: 20 years of follow-up Diabetes 49 Suppl 1 2000 A20
8. K. Malmberg, S. Yusuf, and H.C. Gerstein for the OASIS Registry Investigators Impact of diabetes on long term prognosis in patients with unstable angina and non-Q-wave myocardial infarction. Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry Circulation 102 2000 1014 1019
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2589
10. R.D. Abbott, R.P. Donahue, and W.B. Kannel The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study JAMA 260 1988 3456 3460
11. H. Miettinem, S. Lehto, and V. Salomaa for the FINMONICA Myocardial Infarction Register Study Group Impact of diabetes on mortality after the first myocardial infarction Diabetes Care 21 1998 69 75
12. S.M. Grundy, I.J. Benjamin, and G.L. Burke Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation 100 1999 1134
13. C.C. Cowie, and M.L. Harris M.I. Harris Physical and metabolic characteristics of persons with diabetes. Diabetes in America 2nd edition 1995 National Institutes of Health Washington, DC 117 164
14. C.M. Alexander, P.B. Landsman, and S.M. Teutsch NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older Diabetes 52 2003 1210 1214
15. S.E. Manley, V. Frighi, and E. Stratton for the UK Prospective Diabetes Study Group UK Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex Diabetes Care 20 1997 1683 1687
16. R.C. Turner, H. Millns, and H.A.W. Neil for the UK Prospective Diabetes Study Group Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23) BMJ 316 1998 823 828
17. S.S. Soedamah-Muthu, N. Chaturvedi, and M. Toeller Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study Diabetes Care 27 2004 530 537
18. R. Kreisberg Diabetic dyslipidemia Am J Cardiol 82 1998 67U 73U
19. A.D. Sniderman, T. Scantlebury, and K. Clanfone Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus Diabetes Care 25 2002 579 582
20. K.R. Feingold, C. Grunfeld, and M. Pang LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes Arterioscler Thromb Vasc Biol 12 1992 1496 1502
21. A.D. Sniderman, and K. Cianflone Substrate delivery as a determinant of hepatic apoB secretion Arterioscler Thromb 13 1993 629 636
22. M.R. Taskinen Triglyceride is the major atherogenic lipid in NIDDM Diabetes Metab Rev 13 1997 93 98
23. L. Duvillard, F. Pont, and E. Florentin Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study Eur J Clin Invest 30 2000 685 694
24. S. Rashid, K.D. Uffelman, and G.F. Lewis The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states J Diabetes Complications 16 2002 24 28
25. P.N. Demacker, M.J. Veerkamp, and S.J. Bredie Comparison of the measurements of lipids and lipoproteins versus assay for apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia Atherosclerosis 153 2000 483 490
26. D.L. Tribble, L.G. Holl, and P.D. Wood Variations in oxidative susceptibility among six low-density lipoprotein subfractions of differing density and particle size Atherosclerosis 93 1992 189 199
27. R. Havel Triglyceride-rich lipoproteins and atherosclerosis-new perspectives Am J Clin Nutr 59 1994 795 799
28. W.T. Garvey, S. Kwon, and D. Zheng Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance Diabetes 52 2003 453 462
29. A. Keech, D. Colquhoun, and J. Best Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Results from the LIPID trial Diabetes Care 26 2003 2713 2721
30. K. Pyorala, T.R. Pedersen, and J. Kjekshus Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20 1997 614 620
31. S.M. Haffner, C.M. Alexander, and T.J. Cook Reduced coronary events in simvastatin treated patients with coronary heart disease and diabetes or impaired fasting glucose levels Arch Intern Med 159 1999 2661 2667
32. R.B. Goldberg, M.J. Mellies, and F.M. Sacks Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the Cholesterol And Recurrent Events (CARE) trial Circulation 98 1998 2513 2519
33. J. Shepherd, S.M. Cobbe, and I. Ford for the West of Scotland Coronary Prevention study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
34. J.R. Downs, M. Clearfield, and S. Weis for the AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
35. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
36. P.S. Sever, B. Dahlof, and N.R. Poulter for the ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive subjects who have average or lower-than-average cholesterol concentratons, in the Anglo-Scandinavian Cardiac Outcome Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial Lancet 361 2003 1149 1158
37. Heart Protection Study Collaborative Group MCR/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 5963 People with Diabetes: a randomized placebo-controlled trial Lancet 361 2003 2005 2016
38. Heart Protection Study Collaborative Group MCR/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 High-risk Individuals: a randomized placebo-controlled trial Lancet 360 2002 7 22
39. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
40. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen REVERSAL Investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080
41. For the Pravastatin or Atorvastatin Evaluation Infection Therapy-Thrombolysis in Myocardial Infarction Comparison of intensive and moderate lipid lowering with statins after acute coronary symptoms Obstet Gynecol Surv 59 7 2004 522 524
42. P. Koskinen, M. Manttari, and V. Manniven Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study Diabetes Care 15 1992 820 825
43. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study Circulation 102 2000 21 27
44. H.B. Rubins, S.J. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
45. H.B. Rubins, S.J. Robins, and D. Collins Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Arch Intern Med 162 2002 2597 2604
46. Diabetes Atherosclerosis Intervention Study Investigators Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study Lancet 357 2001 905 910
47. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
48. P.L. Canner, C.D. Furberg, and M.L. Terrin Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol 95 2005 254 257
49. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for prevent of coronary disease N Engl J Med 345 2001 1583 1592
50. S.M. Grundy, J.I. Cleeman, and C.N. Merz Cooordinating Committee of the National Cholesterol Education Program; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
51. American Diabetes Association Dyslipidemia management in adults with diabetes Diabetes Care 27 Suppl 1 2004 S68 S71
52. V. Snow, M.D. Aronson, and E.R. Hornbake Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians Ann Intern Med 140 2004 644 649
53. American Diabetes association Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications Diabetes Care 26 2003 S51 S61
54. S. Yu-Poth, G. Zhao, and T. Etherton Effects of the National Cholesterol Education Program's step I and II dietary intervention program on cardiovascular disease risk factors: a meta-analysis Am J Clin Nutr 69 1999 632 646
55. E.H. Temme, P.G. Van Hoydonck, and E.G. Schouten Effects of a plant sterol-enriched spread on serum lipids and lipoproteins in mildly hypercholesterolemic subjects Acta Cardiol 57 2002 111 115
56. H. Gylling, and T.A. Miettinen Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolemic NIDDM patients before and during sitostanol ester-margarine treatment Diabetol 37 1994 773 780
57. M. Chandalia, A. Garg, and D. Lutjohann Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus N Engl J Med 342 2000 1392 1398
58. J.W. Anderson, L.D. Allgood, and J. Turner Effects of Psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia Am J Clin Nutr 70 1999 466 473
59. M.L. Turley, C.M. Skeaff, and J.I. Mann The effect of a low-fat, high-carbohydrate diet on serum high density lipoprotein cholesterol and triglyceride Eur J Clin Nutr 52 1998 728 732
60. A. Garg High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis Am J Clin Nutr 67 1998 577S 582S
61. D.M. Bravata, L. Sanders, and J. Huang Efficacy and safety of low-carbohydrate diets. A systematic review JAMA 289 2003 1837 1850
62. C.E. Friedberg, M.J.F.M. Janssen, and R. Heine Fish oil and glycemic control in diabetes. A meta-analysis Diabetes Care 21 1998 494 500
63. R.J. Woodman, T.A. Mori, and V. Burke Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension Am J Clin Nutr 76 2002 1007 1015
64. N. Emanuele, N. Azad, and C. Abraira Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus Arch Intern Med 18 1998 2485 2490
65. P.J. Palumbo Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus J Diabetes Complications 12 1998 110 119
66. K. Winkler, T. Konrad, and S. Fullert Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study Diabetes Care 26 2003 2588 2594
67. M.I. Freed, R. Ratner, and S.M. Marcovina Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus Am J Cardiol 90 2002 947 952
68. J.P.H. van Wijk, E.J.P. de Koning, and E.P. Martens Thiazolidinediones and blood lipids in type 2 diabetes Arterioscler Thromb Vasc Biol 23 2003 1744 1749
69. E. Chiquette, G. Ramirez, and R. DeFronzo A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors Arch Int Med 164 2004 2097 2104
70. Goldberg RB, Kendall DM, Deeg MA, et al. Comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in type 2 diabetic patients and dyslipidemia. Presented at the American Heart Association Scientific Sessions, New Orleans, Louisiana, November 2004.
71. T.A. Hillier, and K.L. Pedula Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth Diabetes Care 26 2003 2999 3005
72. M.A. Pfeffer, A. Keech, and F.M. Sacks Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling Project (PPP) Circulation 105 2002 2341 2346
73. S.J. Robins Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line therapy? Curr Opin Lipidol 14 2003 575 583
74. W. Lu, H.E. Resnick, and K.A. Jablonski Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes. The Strong Heart Study Diabetes Care 26 2003 16 23
75. H. Scharnagl, R. Schinker, and H. Gierens Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells Biochem Pharmacol 62 2001 1545 1555
76. L. Pontrelli, W. Parris, and K. Adeli Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes Metabolism 51 2002 334 342
77. A.M. Wagner, A. Perez, and E. Zapico Non-HDl cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients Diabetes Care 26 2003 2048 2051
78. A.D. Sniderman, B. Lamarche, and J. Tilley Hypertriglyceridemic hyperapoB in type 2 diabetes Diabetes Care 25 2002 579 582
79. A.M. Wagner, A. Perez, and F. Calvo Apolipoprotein (B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients Diabetes Care 22 1999 812 817
80. C. Gagne, H.E. Bays, and S.R. Weiss Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia Am J Cardiol 90 2002 1084 1091
81. J.R. Crouse III Hypertriglyceridemia: a contraindication to the use of bile acid binding resins Am J Med 83 1987 243 248
82. A.M. Wagner, O. Jorba, and R. Bonet Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia J Clin Endocrinol Metab 88 2003 3212 3217
83. V.G. Athyros, A.A. Papageorgiou, and V.V. Athyrou Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia Diabetes Care 25 2002 1198 1202
84. M.L. Kashyap, M.E. McGovern, and K. Berra Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia Am J Cardiol 89 2002 672 678
85. L.A. Carlson, A. Hamsten, and A. Asplaund Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid J Intern Med 226 1989 271 276
86. H.R. Superko, and R.M. Krauss Differential effects of nicotinic acid in subjects with different LDL subclass patterns Atherosclerosis 95 1992 69 76
87. J.M. McKenney, J.D. Proctor, and S. Harris A comparison of the efficacy and toxic effects of sustained -vs immediate-release niacin in hypercholesterolemic patients JAMA 271 1994 672 677
88. S.M. Grundy, G.L. Vega, and M.E. McGovern Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes Arch Intern Med 162 2002 1568 1576
89. P. Reaven, and J.L. Witztum Lovastatin, nicotinic acid, and rhabdomyolysis Ann Intern Med 109 1988 597 598
90. M.A. Omar, J.P. Wilson, and T.S. Cox Rhabdomyolysis and HMG-CoA reductase inhibitors Ann Pharmacother 35 2001 1096 1107
91. M.B. Elam, D.B. Hunninghake, and K.B. Davis Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study. A randomized trial JAMA 284 2000 1263 1270
92. J. Shepherd Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety Eur Heart J 16 1995 5 13
93. L.R. Pierce, D.K. Wysowski, and T.P. Gross Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy JAMA 264 1990 71 75
94. A. Tal, M. Rajeshawari, and W. Isley Rhabdomyolysis associated with simvastatin-gemfibrozil therapy South Med J 90 1997 546 547
95. G. Pogson, L. Kindred, and B. Carper Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy Am J Card 83 1999 1146
96. P.B. Duell, W.E. Connor, and D.R. Illingworth Rhabdomyolysis after taking atorvastatin with gemfibrozil Am J Cardiol 81 1998 368 369
97. J. Raimondeau, H. Le Marec, and J.C. Chevallier [Biological myolysis during combined fenofibrate-pravastatin therapy] Presse Med 21 1992 663 664
98. R.L. Ellen, and R. McPherson Long term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia Am J Cardiol 81 1998 60B 65B
99. V. Athyros, A.A. Papageorgiou, and H.A. Hatzikonstandinou Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia Am J Cardiol 80 1997 608 613
100. E.A. Iliadis, and R.S. Rosenson Long-term safety of pravastatin- gemfibrozil therapy in mixed hyperlipidemia Clin Cardiol 22 1999 25 28
101. D.K. Murdock, A.K. Murdock, and R.W. Murdock Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders Am Heart J 138 1999 151 155
102. G.L. Vega, P.T. Ma, and N.B. Cater Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome Am J Cardiol 91 2003 956 960
103. T. Prueksaritanont, J.J. Zhao, and B. Ma Mechanistic studies on metabolic interactions between gemfibrozil and statins Pharmacol Exp Ther 301 2002 1042 1051
104. T. Prueksaritanont, C. Tang, and Y. Qiu Effects of fibrates on metabolism of statins in human hepatocytes Drug Metab Dispos 30 2002 1280 1287
105. B.J. Barker, R.R. Goodenough, and J.M. Falko Fenofibrate monotherapy induced rhabdomyolysis Diabetes Care 26 2003 2482
106. P.H. Jones, and M.H. Davidson Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin Am J Cardiol 95 2005 120 122